M. Sue O'Dorisio MD PhD
Pediatric Neuro-Oncology, Pediatric Solid Tumor Oncology
Professor of Pediatrics
Join to View Full Profile
200 Hawkins DriveIowa City, IA 52242
Phone+1 319-356-3595
Fax+1 319-356-7659
Dr. O'Dorisio is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified pediatric hematologist/oncologist with expertise in the diagnosis and care of children with neuroendocrine tumors, neuroblastoma, and pheochromocytoma/paraganglioma. I specialize in treatment of children with theranostics, using beta emitting and alpha emitting radionuclides.
Education & Training
Ohio State University College of MedicineClass of 1985
University of Nebraska Medical CenterPhD, Biochemistry, 1972
Creighton UniversityBS, Biology and Math, 1967
Nationwide Children's Hospital/Ohio State UniversityResidency, Pediatrics
Certifications & Licensure
IA State Medical License 1999 - 2024
OH State Medical License 1987 - 2006
Awards, Honors, & Recognition
- Lifetime Achievement Award North American Neuroendocrine Tumor Society, 2017
- Distinguished Mentor Award University of Iowa Carver College of Medicine, 2015
- North American Delegate International Atomic Energy Agency of United Nations, 2009
- Join now to see all
Clinical Trials
- Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Start of enrollment: 2017 Sep 29
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 13 citationsPotential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor VorinostatJanet H Pollard, Yusuf Menda, K D Zamba, Mark T. Madsen, M. Sue O'Dorisio
Cancer Biotherapy & Radiopharmaceuticals. 2021-07-12 - 11 citationsAddition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors.David L. Bushnell, Kellie L. Bodeker, Thomas M. O'Dorisio, Mark T. Madsen, Yusuf Menda
Journal of Nuclear Medicine. 2021-01-30 - 6 citationsProspective Analysis of the Impact of 68Ga-DOTATOC Positron Emission Tomography-Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrin...Silvia N Ghobrial, Yusuf Menda, Gideon K. D. Zamba, Sarah L. Mott, Kristin Gaimari-Varner
Pancreas. 2020-09-01
Journal Articles
- Pancreastatin Predicts Survival in Neuroendocrine TumorsSherman SK, Maxwell JE, O'Dorisio MS, O'Dorisio TM, Howe JR, Ann Surg Oncol, 4/22/2014
- GIPR Expression in Gastric and Duodenal Neuroendocrine TumorsSherman SK, Maxwell JE, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR, Journal of Surgical Research, 1/1/2014
- Gastric Inhibitory Polypeptide Receptor (GIPR) Is a Promising Target for Imaging and Therapy in Neuroendocrine TumorsSherman SK, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR, Surgery., 12/1/2013
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
